We are a family-owned company located in the center of Switzerland in Baar, Zug.
Since 2013, we have produced organic health, cosmetics, and nutritional products of the highest quality with documented results to customers in more than 58 countries.
We produce, research, and develop hemp plants with a high yield of CBD and a full spectrum of natural cannabinoids indoor, outdoor, and greenhouses in Switzerland following organic principles, Good Manufacturing Practices (GMP), and ISO 22716-2007.
To help humans and animals live a better life by giving them the highest quality of natural hemp products with documented effects at prices everyone can afford.
For us, natural means following organic principles for every step in the production from seed to harvest without using fertiliser or pesticides.
It also refers to our products' ingredients being natural and without adding artificial or chemical elements to our product formulations.
Our CBD plants are carefully tested before being CO2 extracted, winterized, and decarboxylated up to 95% to improve the hemp oil's quality, potency, and effect.
Our proprietary CO2 extraction process uses pressurized carbon dioxide (CO2) to extract phytochemicals from the cannabis plant. CO2 extraction is the most expensive extraction method. It is widely considered the most effective and safest hemp plant extraction method in the industry. It results in a very pure CBD oil with a full spectrum of cannabinoids, terpenes, flavonoids, nutrients, and antioxidants.
We produce more than 300 different cannabis products from industrial hemp made outdoor, indoor, or in greenhouses following organic principles.
We produce the following categories of cannabis products:
The THC concentration is always less than 0.2% for our full-spectrum CBD oils and less than 0.0% for our broad-spectrum CBD oils, cosmetics, and vape oils.
Our power supply for the production is generated from solar and water energy only and is provided by WWZ.
For our indoor production, we use state-of-the-art LED grow lamps produced in Ireland with an efficiency of 2.8 µmols/joule to minimise our power consumption while generating the highest possible efficiency (PPF) per watt.
We don't use any ineffective light fixtures like high-pressure sodium (HPS) lamps or similar outdated technologies with a short life span and a very low energy efficiency, but only use high-efficiency LED lamps with minimal heat output.
The latest technology application allows us to have one of the highest indoor production efficiencies in the cannabis industry. We maximise the production per square meter by placing multiple layers of plants on top of each other on shelves.
Hemp absorbs more CO2 than any other plant in the World. Hemp absorbs carbon dioxide (CO2) and expels oxygen (O2) into the air for us humans to breathe. Hemp has been proven to absorb more CO2 per hectare than any other known forest or commercial crop, making it ideal for meeting the ever-growing need to decrease CO2 output in the atmosphere.
Unlike many other indoor cannabis producers, we do not add any artificial CO2 sources to our grow rooms to speed up the production process. Instead, we have increased the natural airflow from the air outside and use our hemp plants to actively clean the air by removing CO2 and positively impacting Mother Nature.
Highest quality meaning that we consistently produce products with the optimal cannabinoid profile and terpene content levels by following Good Manufacturing Practices (GMP), testing every production batch, and verifying results in third-party laboratories in Switzerland.
To this date, we never had a single product fail a verification test in a third-party laboratory.
We publish test results (see examples) on our website and give you full transparency and traceability by adding a production batch sticker showing the exact cannabinoid profile on each CBD oil packaging. The QR code on the bottom of our packaging can be scanned to access more information about each CBD oil.
All our CBD oils are protected by dark amber-colored glass bottles to minimize light penetration to extend the durability and potency of the CBD and cannabinoids inside to a minimum of 24 months, usually much longer.
The medical-grade pipettes used for our CBD oils have a printed scale to make dosing easy, protective child-lock, and branded with Formula Swiss printed on the pipettes.
We are committed to documenting the results of our products on humans and animals through independent scientific research studies.
Since 2018, we have been donating CBD products for medical research to hospitals in Bangkok in Thailand.
Together with Dutch researchers, we plan a large double-blinded, randomised placebo-controlled crossover trial study on more than 300 people in The Netherlands using our CBN products on patients with irritable bowel syndrome (IBS) and musculoskeletal pain due to rheumatoid arthritis (RA).
We are in contact with more researchers and scientists to further support cannabis research on humans.
We have a close research collaboration with the University of Bologna and their Department of Veterinary Medical Sciences for a range of studies for the effect of cannabidiol (CBD) in animals.
The Department of Veterinary Medical Sciences is studying the effect of cannabidiol (CBD) in animals. The objective is to increase the understanding of the effect in animals to continue to improve our product development of CBD pet products. With the collaboration between Professor Roberto Chiocchetti´s team of experts researchers and our company, we will gain valuable knowledge about the reactions and results of cannabidiol (CBD) in animals to the benefit of not just the animals but everyone interested in learning more about the effect of cannabinoids for animals.
So far, we have tested CBD on dogs, cats, and horses with positive results.
Our CBD products are registered with Pharmacy Product Number (PPN) by IFA in Germany. IFA is an issuing agency that assigns the Product Registration Agency Code (PRA-Code) for each national numbering system in the pharmaceutical sector. With the PRA code as a prefix, each national product number is transferred into an internationally unique product number (PPN).
All our CBD products - including CBD oils - are also registered as cosmetics in The European Union in the Cosmetic Products Notification Portal (CPNP). Consequently, we are one of the very few European cannabis companies that are not selling our CBD oils as food but as cosmetics, thus not violating The Novel Food catalogue. See more about this subject below.
In Brazil, we have products registered as medical cannabis under ANVISA since 2019. Brazilian doctors are prescribing our products to patients through our network of local distribution partners.
Our CBD oils for animals have been formulated in collaboration with veterinarians, researchers and are officially registered in the Agroscope database for animal food products in Switzerland.
For each of our cosmetics products, we have a very detailed Product Information File (PIF). We have also conducted mandatory skin testing on 50 test persons in independent laboratories in Germany and documented that our products are safe and do not cause any side effects when applied to the skin.
We are proud members of the European Industrial Hemp Association (EIHA) based in Germany, The Swiss Medical Cannabis Association (MEDCAN), The Swiss Hemp Producer Association (IG Hanf) in Bern, and Arge Canna in Austria.
We are shareholders of the EIHA Novel Food Consortium in Germany.
The Novel Food Consortium is a consortium of European hemp producers who have joined forces to submit a joint Novel Food application in the EU and the United Kingdom and share the costs.
The EIHA Novel Food Consortium will invest approximately €3.5 million for financing all relevant and unprecedented toxicological studies on CBD and THC and have hired reputable ChemSafe to conduct the studies.
As a consortium member, we will also apply for a Novel Food status in the United Kingdom under Food Standards Agency.
We support the Swiss Medical Cannabis Association based in Zürich, Switzerland, and make financial contributions to help their mission of legalising medical cannabis in Switzerland.
MEDCAN reports show that between 70,000 to 100,000 patients in Switzerland use cannabis illegally to treat their health conditions and actively fight for the full legalisation of cannabis on all levels in Switzerland.